Laurence Reid, Decibel CEO
Still in preclinical testing for ear gene therapies, Decibel touts small snapshot of chemo-induced hearing loss drug
Though Decibel Therapeutics has largely pivoted toward gene therapies for the inner ear, its lead clinical candidate simply aims to protect cancer patients from chemotherapy …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
